Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
about
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyCell cycle gene networks are associated with melanoma prognosisGene Network Rewiring to Study Melanoma Stage Progression and Elements Essential for Driving MelanomaThe ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functionsMethylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasionProteomic profiling of human keratinocytes undergoing UVB-induced alternative differentiation reveals TRIpartite Motif Protein 29 as a survival factorGenomewide association study for onset age in Parkinson disease.Modeling cancer progression via pathway dependenciesLoss of full length CtBP1 expression enhances the invasive potential of human melanoma.Differentiation of zebrafish melanophores depends on transcription factors AP2 alpha and AP2 epsilon.Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage inIsolation and molecular characterization of circulating melanoma cellsTreatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death.Seriniquinone, a selective anticancer agent, induces cell death by autophagocytosis, targeting the cancer-protective protein dermcidin.Integrative genomics identifies gene signature associated with melanoma ulceration.Targeting Nodal in malignant melanoma cells.Expression and functions of galectin-7 in human and murine melanomasAtaxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathwayFunctional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.Use of gene expression and pathway signatures to characterize the complexity of human melanoma.Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanomaLoss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours.Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma.Slug expression during melanoma progressionUnderexpression of Specific Interferon Genes Is Associated with Poor Prognosis of MelanomaDetection of Exosomal miRNAs in the Plasma of Melanoma Patients.Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasisA new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis.Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.The impact of genomics in understanding human melanoma progression and metastasis.Plasma osteopontin concentrations in patients with cutaneous melanomaVitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early-stage melanoma.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.IGSF9 family proteins.Molecular networks in melanoma invasion and metastasis.Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma.Ataxia-telangiectasia group D complementing gene (ATDC) upregulates matrix metalloproteinase 9 (MMP-9) to promote lung cancer cell invasion by activating ERK and JNK pathways.Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma.
P2860
Q27852482-5A11AFF2-0503-4E6F-BA4E-96A224C65CD4Q28482466-305F6770-D759-4976-8C00-70E77D707D64Q28550898-24679287-4721-45A6-B958-BB26B849BC5EQ28593750-358AC5E1-7E4D-47E4-A25A-125167C25794Q28741295-46FC152F-BEEB-41B8-8A9A-29BE4E3A9DAFQ28752381-1931FDF7-A42E-4DD9-8F78-AFEE3CF62EB7Q29417034-0B9B62A8-3A42-4770-BC70-D031AC1CB782Q33320177-0C684A42-5AC8-4F55-936D-6179B331FAC9Q33409095-AAFD9ABC-DDD9-4AD2-8333-D1DB64C4CB06Q33700553-51E75445-BFC8-467A-88B7-7A1C10874116Q33710045-1AFA3CFB-2C89-4237-BC95-11C50A694AA2Q33835938-3221E543-A212-48CB-ADF4-DE2256B74F42Q33847750-4BBE0536-F7E8-43F8-B7E4-17B070378DB3Q34384010-E55F543D-F15A-446F-86A0-EC4C1F35A7ACQ34575854-20B9FB12-7180-4C97-9446-7EC3E9406B2EQ34610503-204E22C5-7DB0-49DF-B852-4BDB51AE443BQ34713124-4EC4A9BD-60F5-4204-849E-0B8385DA8B15Q34775578-3480E0A3-ADED-4925-A853-3CE7E9FD6A07Q34972522-53F7FD1F-8087-47D5-B394-D9A08A8C9440Q35071486-13CEDD95-0ED5-48AD-8636-613F8696FBE7Q35091482-17E61985-E2DF-4114-9C12-1F568F74B9F9Q35145922-E8869FBB-D110-4371-B6EE-EB25508B4BF4Q35234272-279CCF8F-0BFB-469C-9A5F-9A62E0B0A60EQ36044631-397923B3-4AEE-452A-A70D-79B3834E8411Q36257430-EBE9480C-5483-47B3-AD0D-5CEBA80203FEQ36409368-8E6AED9A-9BB6-41D4-BA5E-38EFE4FFC77DQ36590628-0B03A872-9F9D-41A9-BDEA-46F02E6EF216Q36691376-E2886F70-CD30-4520-B758-7570BEC82B46Q36773305-645D99BD-D6C5-4442-965C-1A59D0F51F77Q36984855-F935FF4D-E9FA-4AA5-B200-9568FC64359DQ37112466-61CE3746-E07F-4529-BF23-6950BAF90584Q37205801-902398D4-A270-494A-B471-AB45EB444931Q37260595-11F487D6-B031-4175-A713-792BC9EAF165Q37384738-A3CDAB75-CD55-4B90-BDD5-79A758FDD4F5Q37406706-CB20513D-B3F5-43D4-A236-84ADC9F0E43EQ38082408-62722F2E-A6C5-4A78-B0EC-220584081779Q38104416-951BEFEF-26BE-4F91-B237-A8B7685E6840Q38713402-E2486632-A81A-4FDD-94BC-D16CF63FEAF5Q39150831-BC5C1DB5-25FE-4BDF-8C4D-B488728865B3Q39397994-1805B504-4CDE-4C2A-B470-6F701A3911F1
P2860
Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Whole-genome expression profil ...... and advanced-stage melanomas.
@en
type
label
Whole-genome expression profil ...... and advanced-stage melanomas.
@en
prefLabel
Whole-genome expression profil ...... and advanced-stage melanomas.
@en
P2093
P356
P1476
Whole-genome expression profil ...... and advanced-stage melanomas.
@en
P2093
Amanda Pfaff Smith
Dorothea Becker
Keith Hoek
P304
P356
10.4161/CBT.4.9.2165
P577
2005-09-09T00:00:00Z